Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGFR | P43088 | 5/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397377 | 1.00 | ABCB11 (0.58) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL10104086 | 1.00 | ABCB11 (0.58) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL397379 | 1.00 | ABCB11 (0.58) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL397376 | 1.00 | ABCB11 (0.58) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL10104321 | 0.95 | ABCB11 (0.52) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL10104123 | 0.94 | PTGS1 (0.54) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL396960 | 0.94 | ABCB11 (0.66) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL396276 | 0.94 | ABCB11 (0.66) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL396275 | 0.94 | ABCB11 (0.66) | ABCB11AKR1C3PTGS1PTGFRPTGER3 | |
| SCHEMBL396277 | 0.94 | ABCB11 (0.66) | ABCB11AKR1C3PTGS1PTGFRPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | ABCB11 2484/4885AKR1C3 482/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.